Glucotrack (GCTK) Cash & Current Investments (2010 - 2025)

Glucotrack (GCTK) has 16 years of Cash & Current Investments data on file, last reported at $7.4 million in Q4 2025.

• Quarterly Cash & Current Investments rose 31.44% year-over-year to $7.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7.4 million (up 31.44% YoY) and the FY2025 annual result came in at $7.4 million, up 31.44% from the prior year.
• Cash & Current Investments declined to $7.4 million in Q4 2025, from $9.1 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $9.1 million in Q1 2025 to a low of $159000.0 in Q2 2024.
• A 5-year average of $5.0 million and a median of $5.2 million in 2022 frame the typical range for Cash & Current Investments.
• Annual changes were most pronounced in 2024 — Cash & Current Investments sank 98.19% — and 2025, when it surged 507.88%.
• Tracing GCTK's Cash & Current Investments over 5 years: stood at $6.1 million in 2021, then plunged by 61.86% to $2.3 million in 2022, then jumped by 94.29% to $4.5 million in 2023, then climbed by 25.04% to $5.6 million in 2024, then surged by 31.44% to $7.4 million in 2025.
• The last three Cash & Current Investments figures came in at $7.4 million (Q4 2025), $9.1 million (Q1 2025), and $5.6 million (Q4 2024), per Business Quant data.